<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P01394200A0592 The treatment group also showed in vivo T-cell activation with an initial lymphopenia followed by a rebound lymphocytosis and upregulation of the subset markers CD25 (interleukin 2 receptor) and CD45RO (T-memory cells)."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="234" language="x-unspecified"/><edu.cmu.tanl.type.gene _indexed="1" _id="13" _ref_sofa="1" begin="137" end="140" Gene="CD25"/><edu.cmu.tanl.type.gene _indexed="1" _id="18" _ref_sofa="1" begin="142" end="161" Gene="interleukin 2 receptor"/><edu.cmu.tanl.type.gene _indexed="1" _id="23" _ref_sofa="1" begin="166" end="171" Gene="CD45RO"/><edu.cmu.tanl.type.gene _indexed="1" _id="28" _ref_sofa="1" begin="173" end="173" Gene="T"/></CAS>